Technology
Biology Technology
Microbix Biosystems Re-files Annual Results With OSC
| 11/6/2009 | TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (the "Company") announces today that it has re-filed the Form 52-109F1 Certification of Annual Filings of William Gastle, the Chief Executive Officer and James Long, the Chief Financial Officer (the "Officer's Certificates") dated January 12, 2009 in connection with the annual audited financial statements for the year ended... [Comments] |
Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
| 11/6/2009 | LYNBROOK, N.Y., Nov. 6 BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009. "We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommend... [Comments] |
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th
| 11/6/2009 | AURORA, Ontario, Nov. 6 Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading produ... [Comments] |
| 11/6/2009 | QUINCY, Mass., Nov. 6 Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement & construction (EPC) of Myria... [Comments] |
| 11/6/2009 | VIENNA, Austria, November 6 EUCODIS Bioscience, a companydeveloping, customizing, manufacturing, and marketing enzymes for thechemical industry announced today that it has entered into a researchagreement with Bio Sidus, the leading biopharmaceutical company in LatinAmerica. The agreement gives EUCODIS Bioscience exclusive access - for the searchof enzym... [Comments] |
NeurogesX Reports Third Quarter 2009 Results
| 11/6/2009 | SAN MATEO, Calif., Nov. 6 3Q09 Corporate Highlights: Completed transfer of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd. Made significant progress in commercial readiness activities Expanded management team to include VP Sales; Senior Director, Marketing; and Director, Commercial Operations Appointed Bradford S. Good... [Comments] |
| 11/6/2009 | SPRING VALLEY, Calif., Nov. 6 Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus. Dengue virus is a mosquito-born flavivir... [Comments] |
| 11/6/2009 | CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th.... [Comments] |
| 11/6/2009 | HAYWARD, Calif., Nov. 6 Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA: (Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) Continuous Subcutaneous Deliver... [Comments] |
| 11/6/2009 | The agenda for Arrowhead’s 2010 Personalized Medicine Partnerships Conference, which is set to take place on February 22-24, 2010 in Philadelphia, has been announced. At this three day conference we will highlight key issues in forming partnerships and engage the best speakers to share their experiences. Minneapolis, MN (PRWEB) November... [Comments] |
November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory
| 11/5/2009 | TRANSPORTATION -- Gone hybrid . . . Fuel economy ratings for the new 2010 model year automobiles are now posted at the www.fueleconomy.gov web site, which Oak Ridge National Laboratory developed and maintains for the U.S. Department of Energy and the U.S. Environmental Protection Agency. Nine of the top 10 vehicles on the best fuel economy list are hybrid electrics, led by the Toyot... [Comments] |
Medicine Technology
SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
| 11/6/2009 | BOTHELL, Wash., Nov. 6 SCOLR Pharma, Inc. (Amex: DDD ) today reported financial results for the three and nine months ended September 30, 2009. Stephen J. Turner, SCOLR Pharma's President and CEO, said, "We continue to advance discussions related to licensing our 12-hour ibuprofen formulation. Several potential partners have committed significant resource... [Comments] |
Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
| 11/6/2009 | DURHAM, N.C., Nov. 6 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that a previously approved reverse split of its common stock will take effect at the start of trading on Monday, Nov. 9, 2009 on a 1-for-15 split-adjusted basis. Oxygen Biotherapeutics, Inc. shares will trade under the new symbol OXBT. The stock also will have a new CUSIP... [Comments] |
Recession Continues to Depress Sales at Allied Healthcare Products
| 11/6/2009 | ST. LOUIS, Nov. 6 Recession in domestic and international markets continued to depress sales for Allied Healthcare Products in the first quarter of fiscal year 2010 ending September 30, 2009. Sales declines pushed Allied into a loss for the quarter. The net loss for the quarter was about $745,000, or negative 9 cents per share, compared to a net profit the... [Comments] |
| 11/6/2009 | FORT WASHINGTON, Pa., Nov. 6 In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is initiating a voluntary recall of a limited number of product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP. McNeil is initiating the recall after identifyin... [Comments] |
DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
| 11/6/2009 | WILMINGTON, Mass., Nov. 6 DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curha... [Comments] |
Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
| 11/6/2009 | SAN DIEGO, Nov. 6 Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company. Credit Suisse Securities (USA) LL... [Comments] |
Watson to Present at Credit Suisse Healthcare Conference
| 11/6/2009 | MORRISTOWN, N.J., Nov. 6 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, 2009 at 12:00 pm Eastern St... [Comments] |
Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results
| 11/6/2009 | OAKLAND, Calif., Nov. 6 Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals (KFHP/H), and their subsidiaries reported today a combined total operating revenue of $10.5 billion for the quarter ended September 30, 2009, compared to $10.2 billion in the third quarter of last year. Operating income in the third quarter was $336 million, compared to $307 million in... [Comments] |
NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009
| 11/6/2009 | WESTBURY, N.Y., Nov. 6 Repossessions and liquidations of trucking equipment and machine tools in the third quarter of 2009 declined as compared to similar figures from 2008, according to Nassau Asset Management's NasTrac Quarterly Index (NQI). The figures, culled from the company's activity reports for both repossessions and orderly liquidations, also indicated a rise in r... [Comments] |
| 11/6/2009 | SARASOTA, Fla., Nov. 6 Roper Industries, Inc. (NYSE: ROP) today announced that it has signed a definitive agreement to acquire Verathon, Inc., a leading provider of proprietary medical devices. The Verathon Board of Directors has approved the transaction and the closing is subject to customary regulatory approvals and closing conditions, including shareholder... [Comments] |
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
| 11/6/2009 | DETROIT, Nov. 6 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® ophthalmic solution on the first day following patent expiration. This s... [Comments] |
(Date:11/6/2009)... The agenda for Arrowhead’s 2... which is set to take place on February 22-24, 201...ee day conference we will highlight key issues in ...to share their experiences. , ...he agenda for Arrowhead’s 2010 Personalized...
(Date:11/5/2009)...DIEGO, Nov. 5 Imagenetix... that William Spencer, President and CEO of Imagen...e 2nd annual LD MICRO Conference on Thursday, Dece...s Angeles. ,, About LD MICRO ,, LD MICRO is ...on finding undervalued companies in the micro-cap ...
(Date:11/5/2009)...YVALE, Calif., Nov. 5 Ce...ecutives will be speaking at the following investo...e via webcast. , , Credit Suisse H... Thursday, 12 November, 2009 at 10 a.m. Mountain T...gram, London, England, Tuesday, 1 ...
(Date:11/5/2009)...PLYMOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-Fir... ) ("BMP Sunstone" or the "Company") today announc... 2009 financial results on,Monday, November 9, 200... will hold a conference call at 5:00 pm ET on Nove.... Listeners may access the call by,dialing 1-888-...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Cepheid to Webcast Upcoming Financial Presentations 2BMP Sunstone to Report Third Quarter 2009 Financial Results 2[0] Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference[0] Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air[0] Cepheid to Webcast Upcoming Financial Presentations[0] BMP Sunstone to Report Third Quarter 2009 Financial Results
...ration and Gene Company, Ltd.,announced today the ...y,will sell and service the Amnis ImageStream(R) s...fic research communities in Hong Kong, Shanghai,Be...ant cell analysis,technology., "We are extremely ...uable partnership with Gene Company. We are lookin...
... Call Scheduled for Tuesday, May 13th at 5 PM ET, ...asdaq: IMRX ) today announced that the Company wi...day, May 13, 2008, at 5:00 p.m. ET to discuss,firs...st can be accessed through ImaRx,s corporate websi...on the website for 14 days following the,event., ...
...uidance for 2008, SAN DIEGO, May 7 Volcano Corpo...developer of intravascular ultrasound,(IVUS), func...graphy (OCT),products designed to enhance the diag...cular disease, today reported results for the firs...March 31, 2008, Volcano reported revenues of,$36.6...
Other Biology Technology:Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China 2Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 2Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 3Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 4Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 5Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 6Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 7Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 8Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 9Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 10Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 11Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 12Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent 13(Date:11/6/2009)...ON, S.C., Nov. 6 The ...n South Carolina and Georgia throughout the week o... uninsured and financially-struggling patients acc...ion medicines for free or nearly free. With the na... the Partnership for Prescription Assistance (PPA)...
(Date:11/6/2009)...Mass., Nov. 6 Boston Sci...that it has reached an agreement in principle with...roduct advisories issued by its Guidant subsidiary...ccurred prior to Boston Scientific,s 2006 acquisit...usly disclosed an investigation by the U.S. Attorn...
(Date:11/6/2009)..., Nov. 6 Keryx Biopharma...rence call on Tuesday, November 10, 2009 at 8:30 a...l results and business outlook for the remainder o...he Company, will host the call. Keryx will announ...s release to be issued prior to the call. ,, In...
Breaking Medicine Technology:Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Biologists devise unifying framework to explain evolutionary puzzles 8721 1Biologists devise unifying framework to explain evolutionary puzzles 8721 2LOHAS Announces Final Program Line up Including Speakers from Wal Mart Coca Cola MINI Facebook Causes Saatchi 26 SaatchiS Gaiam and eBay 47970 1LOHAS Announces Final Program Line up Including Speakers from Wal Mart Coca Cola MINI Facebook Causes Saatchi 26 SaatchiS Gaiam and eBay 47970 2Avoid the Burn 3A First Sunscreen to Earn the Melanoma International Foundation Seal of Approval Expands Distribution Throughout Northern California 47968 1Avoid the Burn 3A First Sunscreen to Earn the Melanoma International Foundation Seal of Approval Expands Distribution Throughout Northern California 47968 2Avoid the Burn 3A First Sunscreen to Earn the Melanoma International Foundation Seal of Approval Expands Distribution Throughout Northern California 47968 3[0] Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession[0] Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant[0] Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
...Will facilitate tight integration between sponsors...Velos, Inc., a recognized,leader and trusted resou...ems and member of the Oracle PartnerNetwork, will ...earch and Oracle Clinical. Both software,products ...h is widely,installed at research sites, while Ora...
...Potential First-in-Class Treatment for Type 2 Diab...., a,biopharmaceutical company focused on the disc... for the treatment of metabolic diseases,announced...hy subjects in a,Phase 1 clinical trial of MBX-298... diabetes., The Phase 1 clinical trial will evalu...
Other Medicine Technology:Velos to Develop Key System Interface for Clinical Research 2Velos to Develop Key System Interface for Clinical Research 3Velos to Develop Key System Interface for Clinical Research 4Metabolex Initiates Phase 1 Trial of MBX-2982 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |